这份2026年3月初的NMPA药品批准证明文件,透着一股不寻常的火药味。长达75项的名单中,绝大多数是仿制药和常规注射液在红海里苦苦厮杀。但在表格的隐秘角落,几股真正能搅动行业格局的力量正在悄然落子:亚虹医药拿下了全球首个针对CIN2的非手术无创治疗产品(APL-1702);轩竹生物的重磅CDK4/6抑制剂吡咯西利赫然在列;而跨国巨头赛诺菲的“百亿药王”度普利尤单抗(Dupixent),则一口气...
Source Link这份2026年3月初的NMPA药品批准证明文件,透着一股不寻常的火药味。长达75项的名单中,绝大多数是仿制药和常规注射液在红海里苦苦厮杀。但在表格的隐秘角落,几股真正能搅动行业格局的力量正在悄然落子:亚虹医药拿下了全球首个针对CIN2的非手术无创治疗产品(APL-1702);轩竹生物的重磅CDK4/6抑制剂吡咯西利赫然在列;而跨国巨头赛诺菲的“百亿药王”度普利尤单抗(Dupixent),则一口气...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.